Boston Scientific Cash Flow from Financial Activities 2010-2025 | BSX
Boston Scientific annual/quarterly cash flow from financial activities history and growth rate from 2010 to 2025. Cash flow from financial activities can be defined as the net amount of cash transactions used in funding activities
- Boston Scientific cash flow from financial activities for the quarter ending March 31, 2025 was $1.814B, a 36180% increase year-over-year.
- Boston Scientific cash flow from financial activities for the twelve months ending March 31, 2025 was $6.576B, a 6676% decline year-over-year.
- Boston Scientific annual cash flow from financial activities for 2024 was $1.814B, a 36180% increase from 2023.
- Boston Scientific annual cash flow from financial activities for 2023 was $0.005B, a 100.91% decline from 2022.
- Boston Scientific annual cash flow from financial activities for 2022 was $-0.548B, a 476.84% increase from 2021.
| Boston Scientific Annual Cash Flow Financial (Millions of US $) |
|
|---|---|
| 2024 | $1,814 |
| 2023 | $5 |
| 2022 | $-548 |
| 2021 | $-95 |
| 2020 | $293 |
| 2019 | $2,973 |
| 2018 | $1,432 |
| 2017 | $110 |
| 2016 | $-206 |
| 2015 | $1,276 |
| 2014 | $-150 |
| 2013 | $-624 |
| 2012 | $-764 |
| 2011 | $-1,728 |
| 2010 | $-508 |
| 2009 | $-820 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $152.176B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $231.816B | 27.87 |
| Stryker (SYK) | United States | $145.393B | 30.40 |
| EssilorLuxottica (ESLOY) | France | $127.544B | 0.00 |
| Medtronic (MDT) | Ireland | $107.067B | 15.63 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.941B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.416B | 27.54 |
| ResMed (RMD) | United States | $35.930B | 26.99 |
| GE HealthCare Technologies (GEHC) | United States | $31.992B | 15.19 |
| Agilent Technologies (A) | United States | $30.486B | 20.14 |
| Terumo (TRUMY) | Japan | $28.205B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $23.066B | 16.58 |
| Insulet (PODD) | United States | $21.859B | 85.82 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.837B | 12.10 |
| Baxter (BAX) | United States | $15.857B | 11.84 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.412B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $8.030B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.686B | 22.60 |
| Lantheus Holdings (LNTH) | United States | $5.655B | 14.27 |
| Prestige Consumer Healthcare (PBH) | United States | $4.325B | 19.27 |
| Perrigo (PRGO) | Ireland | $3.713B | 9.41 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.426B | 14.92 |
| ICU Medical (ICUI) | United States | $3.404B | 25.10 |
| Envista Holdings (NVST) | United States | $2.981B | 24.77 |
| QuidelOrtho (QDEL) | United States | $2.458B | 16.90 |
| GN Store Nord (GNNDY) | Denmark | $2.075B | 17.18 |
| LeMaitre Vascular (LMAT) | United States | $1.813B | 40.53 |
| AtriCure (ATRC) | United States | $1.534B | 0.00 |
| Neogen (NEOG) | United States | $1.296B | 16.58 |
| Green Thumb Industries (GTBIF) | United States | $1.173B | 26.38 |
| Kestra Medical Technologies (KMTS) | United States | $1.164B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.156B | 11.75 |
| BioLife Solutions (BLFS) | United States | $1.106B | 0.00 |
| InMode (INMD) | Israel | $1.005B | 9.20 |
| Phibro Animal Health (PAHC) | United States | $0.910B | 11.64 |
| Evolus (EOLS) | United States | $0.632B | 0.00 |
| CeriBell (CBLL) | United States | $0.577B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.557B | 0.00 |
| Owens & Minor (OMI) | United States | $0.542B | 4.49 |
| Valneva SE (VALN) | France | $0.541B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.504B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.431B | 0.00 |
| Surmodics (SRDX) | United States | $0.383B | 0.00 |
| Omeros (OMER) | United States | $0.360B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.358B | 0.00 |
| SNDL (SNDL) | Canada | $0.339B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.290B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.288B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.283B | 10.42 |
| Aurora Cannabis (ACB) | Canada | $0.273B | 48.50 |
| Sanuwave Health (SNWV) | United States | $0.258B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.250B | 21.07 |
| Verano Holdings (VRNOF) | United States | $0.248B | 0.00 |
| Cerus (CERS) | United States | $0.247B | 0.00 |
| ZimVie (ZIMV) | United States | $0.244B | 11.09 |
| Canopy Growth (CGC) | Canada | $0.241B | 0.00 |
| Biote (BTMD) | United States | $0.219B | 6.15 |
| Quanterix (QTRX) | United States | $0.205B | 0.00 |
| High Tide (HITI) | Canada | $0.194B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.188B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.176B | 14.18 |
| Brainsway (BWAY) | Israel | $0.164B | 51.24 |
| TriSalus Life Sciences (TLSI) | United States | $0.162B | 0.00 |
| Organigram Global (OGI) | Canada | $0.158B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.147B | 18.16 |
| Jin Medical (ZJYL) | China | $0.130B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.110B | 0.00 |
| Exagen (XGN) | United States | $0.103B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.094B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.092B | 0.00 |
| MacroGenics (MGNX) | United States | $0.090B | 0.00 |
| Agape ATP (ATPC) | $0.078B | 0.00 | |
| Fonar (FONR) | United States | $0.077B | 10.77 |
| Veru (VERU) | United States | $0.074B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.073B | 0.00 |
| InterCure (INCR) | Israel | $0.072B | 0.00 |
| Zynex (ZYXI) | United States | $0.063B | 0.00 |
| United Health Products (UEEC) | United States | $0.059B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.055B | 0.00 |
| ImmuCell (ICCC) | United States | $0.046B | 0.00 |
| Apyx Medical (APYX) | United States | $0.044B | 0.00 |
| Modular Medical (MODD) | United States | $0.041B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.038B | 56.00 |
| United-Guardian (UG) | United States | $0.037B | 12.79 |
| Safety Shot (SHOT) | United States | $0.037B | 0.00 |
| Nephros (NEPH) | United States | $0.020B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.018B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |